Key facts
- This page summarizes Michael W. Kalb's Form 4 filing for IMPEL PHARMACEUTICALS INC.
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 12 May 2023, 16:41.
Michael W. Kalb - 10 May 2023 Form 4 Insider Report for IMPEL PHARMACEUTICALS INC
- SEC form
- 4
- Accepted by SEC
- 12 May 2023, 16:41:42 UTC
- Prior SEC filing
- 24 Feb 2023
- Next SEC filing
- 03 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adrian Adams as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael W. Kalb filed Form 4 for IMPEL PHARMACEUTICALS INC on 12 May 2023.
Change
- Previous filing in this sequence was filed on 24 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMPL
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +175,000
- Change %
- Price
- $0.000000
- Shares after
- 175,000
- Date
- 10 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 175,000
- Exercise price
- $2.43
- Footnotes
- F1
IMPL
transaction
Derivative
Restricted Stock Units (RSUs)
Award
- Transaction value
- $0
- Shares
- +47,500
- Change %
- Price
- $0.000000
- Shares after
- 47,500
- Date
- 10 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 47,500
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The option vests as to 25% of the total shares on May 10, 2024 and then 1/48th of the total shares vests on each monthly anniversary thereafter, subject to the reporting person's provision of service to the issuer on each vesting date.
Footnote F2
Each RSU represents a contingent right to receive 1 share of the issuer's Common Stock upon settlement.
Footnote F3
The RSUs vest as to 100% of the total shares on May 31, 2024, subject to the reporting person's continuation of employment on such vesting date.